Pentoxifylline added for Eisenmenger syndrome
Treatments studied
Part of Genetic & congenital, Heart & circulation, Lungs & breathing clinical trials.
This study tests whether adding pentoxifylline to usual care can improve health outcomes in people with Eisenmenger syndrome. It may help reduce problems related to blood flow and vessel function, especially for those not recently hospitalized.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Eisenmenger syndrome and your symptoms are Class II, III, or IV (based on World Health Organization grading for pulmonary hypertension).
- You can be taking warfarin or not taking any blood thinner by mouth.
- You are not currently in the hospital.
- You have no history of repeated or significant bleeding.
- Your blood platelets are not too low (more than 80,000 per microliter).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called sotatercept for people with Eisenmenger syndrome or a related heart defect that hasn't been repaired. It may help if current treatments aren't working well enough.
This trial tests a drug called sotatercept for people with Eisenmenger syndrome caused by certain unrepaired heart defects. It aims to see if the drug can improve exercise ability and overall well-being.
This trial tests whether adding pentoxifylline (a medication that improves blood flow) to your current psoriasis cream treatment helps reduce psoriasis patches. You'll be on stable topical therapy for at least 2 weeks, then the study will see if the added medication improves your skin.
This trial tests if pentoxifylline, a medicine used for blood flow, can reduce calcium buildup in blood vessels for people with moderate-to-severe chronic kidney disease who are not yet on dialysis.
This trial tests whether adding the medicine pentoxifylline to standard care can help people with ulcerative colitis. It’s designed to see if this combination improves symptoms by changing inflammation.
This study tests if pentoxifylline, a medicine typically used for circulation, can help reduce joint inflammation in people with rheumatoid arthritis who still have active symptoms despite taking standard DMARDs.
Hear when a new Eisenmenger Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.